Long-Acting Injectables Patient Advisory Committee
Quick links
ADAP Advocacy is currently recruiting patients and public health stakeholders to serve on its Long-Acting Injectables Patient Advisory Committee.
Committee Members
The committee is open to adding new discussion topics to its meeting agenda. Click here to submit your thoughts to Warren O’Meara-Dates, chair of the Long-Acting Injectables Patient Advisory Committee.
May 7, 2026
April 28, 2025
BACK TO TOPCommittee Meetings
U.S. Food & Drug Administration (FDA)
FDA Approves Sunlenca for Adults With Resistant HIV (December 2022)*
FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention (December 2021)
FDA Approves Cabenuva and Vocabria for the Treatment of HIV-1 Infection (January 2021)
FDA approves new HIV treatment for patients who have limited treatment options (March 2018)
FDA Approves Egrifta to Treat Lipodystrophy in HIV Patients (November 2010)
* Press statement no longer available on FDA's websiteHIV+Hep Policy Institute
O’Neill Institute for National and Global Health Law at Georgetown University
Positively Aware Magazine
Guide to Long-Acting Injectables for HIV (August 2024)
Attitudes and Access: Survey Results on Long-Acting Injectables for HIV (June 2024)
BACK TO TOPCommittee Resources
This project is funded by the following corporate entities:
Gilead Sciences, Merck, and ViiV Healthcare.
Transparency statement:
To read our Transparency Statement, click here.
BACK TO TOP